Claims

1. Use of a compound represented by general structure (**I**):



(**I**)

wherein,

- T is represented by structure (IIIa) or (IIIb):



(IIIa) (IIIb)

wherein each R7 is individually a C1-C6 alkyl moiety, preferably each R7 is methyl;

- L is a linker between the amide nitrogen atom and N* comprising 1 to 10 optionally substituted backbone atoms selected from carbon, nitrogen and oxygen;
- N* is represented by structure (**IIa**) or (**IIb**)



(**IIa**) (**IIb**)

wherein N* can be part of an imine moiety, in which case the linker L comprises at least one double bond located between N* and the adjacent backbone atom of the linker, or R^2 comprises at least one double bond located between N* and the adjacent atom of R^2;

- R^1 and R^2 are each independently selected from hydrogen (H), C_1 – C_6 alkyl or C_1 – C_6 alkenyl, or R^1 and R^2 are joined together and thus form a second linker between the amide nitrogen atom and N*, or R^1 is joined with a backbone atom of the linker L in a cyclic structure and/or R^2 is joined with a backbone atom of the linker L in a cyclic structure;
- R^3 is selected from hydrogen (H), C_1 – C_6 alkyl or C_1 – C_6 alkenyl, wherein the alkyl or alkenyl moiety may be substituted with one or more halogen atoms, hydroxyl moieties or (halo)alkoxy moieties, or R^3 is absent when N* is part of an imine moiety; or optionally R^3 is joined with a backbone atom of the linker L in a cyclic structure; and
- R^4 is selected from hydrogen (H) or C_1 – C_6 alkyl, wherein the alkyl moiety may be substituted with one or more halogen atoms or (halo)alkoxy moieties;
- X is an anion, preferably a pharmaceutically acceptable anion,

in the manufacture of a medicament for preventing or suppressing symptoms mediated by enhanced mPGES-1 expression or activity , wherein the medicament is for preventing or

suppressing symptoms mediated by enhanced mPGES-1 expression or activity in the treatment of a disease or condition selected from the group consisting of:

a) acute and chronic inflammation; dermatitis, eczema, bums, acne vulgaris, hidradenitis suppurativa and tissue trauma; inflammatory bowel disease, Crohn's disease, ulcerative colitis, diverticulitis, irritable bowel disease (IBS), peptic ulcers, cystitis, (chronic) prostatitis, or nephritis; ear, nose, mouth and throat disease such as influenza, rhinitis, pharyngitis, tonsillitis, conjunctivitis, iritis, scleritis, otitis and uveitis; viral and bacterial infections; inflammation related anorexia; an allergy; pelvic inflammatory disease; transplant rejection; tendinitis, vasculitis and phlebitis;

b) acute pain, chronic pain, neuropathic pain, nociceptive pain, hyperalgesia, pain related to central sensitization, allodynia inflammatory pain, visceral pain, cancer pain, trauma pain, dental or surgery pain, postoperative pain, delivery pain, childbirth ache, persistent pain, peripheral mediated pain, central mediated pain, chronic headache, migraine, sinus headaches, tension headaches, phantom limb pain, peripheral nerve injury chemotherapy pain, and cancer pain;

c) ankylosing spondylitis, gout, rheumatic fever, or bursitis;

d) chronic obstructive pulmonary disease (COPD), or pulmonary fibrosis;

e) brain cancer, prostate cancer, kidney cancer, liver cancer, pancreatic cancer, gastric cancer, breast cancer, head and neck cancer, thyroid cancer, glioblastoma, melanoma, lymphoma, leukemia, skin T-cell lymphoma and skin B-cell lymphoma;

f) diabetic complications including diabetic vasculopathy, diabetic neuropathy and diabetic retinopathy;

h) atherosclerosis, thrombosis, and coronary heart disease.

2. The use according to claim 1, wherein the compound is represented by structure (**VI**):



(**VI**)

wherein N* is $–NR^3$ or $–N^+R^3R^4\ X^–$, wherein T, X, R^3, and R^4 are as defined in claim 1.

3. The use according to claim 1 or claim 2, wherein the compound is represented by structure (**VIIb**):



(**VIIb**)

wherein

each R^7 is methyl;

N^* is $–NR^3$ or $–N^+R^3R^4\ X^–$;

X is as defined in claim 1 and is preferably Cl^-;

R^3 is as defined in claim 1 and is preferably hydrogen; and

R^4 is as defined in claim 1 and is preferably hydrogen.

4. The use according to any one of claims 1 – 3, wherein the symptoms mediated by enhanced mPGES-1 expression or activity at least include one or more of inflammation, pain, swelling, fever, angiogenesis and anorexia.

5. The use according to any one of claims 1 – 4, wherein the total daily dose that is to be administered is in the range of 5 to 2000 mg, preferably 20 to 800 mg, more preferably the total daily dose is in the range of between 30 to 400 mg and most preferably the total daily dose is in the range of 150 to 250 mg.

6. The use according to any one of claims 1 – 5, wherein the medicament is to be administered orally.

7. The use according to any one of claims 1 – 6, wherein the medicament is to be administered in a solid form or in a liquid form, wherein preferably the compound is admixed with an aqueous solution prior to administration, wherein more preferably the aqueous solution is an isotonic aqueous solution and wherein even more preferably the isotonic aqueous solution is saline.

8. The use according to any one of claims 1 – 7, wherein the medicament is to be administered at least twice daily, preferably wherein the compound is to be administered twice daily, wherein more preferably the compound is to be administered twice daily in two similar or equal doses.

9. The use according to claim 8, wherein the interval between two administrations is at least about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 hours.

10. The use according to any one of claims 1 – 9, wherein the subject to be treated is a primate, wherein preferably the subject is a human.